Research output per year
Research output per year
Personal profile
Fields of Science
- 3122 Cancers
International and National Collaboration
Publications and projects within past five years.
-
Edenneen munuaissyövän hoito
Mattila, K., Peltola, K. & Jaakkola, P., 2022, In: Duodecim. 138, 17, p. 1525-1533 9 p.Research output: Contribution to journal › Review Article › peer-review
Open AccessFile -
A three-feature prediction model for metastasis-free survival after surgery of localized clear cell renal cell carcinoma
Mattila, K. E., Laajala, T. D., Tornberg, S. V., Kilpeläinen, T. P., Vainio, P., Ettala, O., Bostrom, P. J., Nisen, H., Elo, L. L. & Jaakkola, P. M., 21 Apr 2021, In: Scientific Reports. 11, 1, 8 p., 8650.Research output: Contribution to journal › Article › Scientific › peer-review
Open AccessFile -
Systemic Blockade of Clever-1 Elicits Lymphocyte Activation Alongside Checkpoint Molecule Downregulation in Patients with Solid Tumors: Results from a Phase I/II Clinical Trial
Virtakoivu, R., Rannikko, J. H., Viitala, M., Vaura, F., Takeda, A., Lonnberg, T., Koivunen, J., Jaakkola, P., Pasanen, A., Shetty, S., de Jonge, M. J. A., Robbrecht, D., Ma, Y. T., Skyttä, T., Minchom, A., Jalkanen, S., Karvonen, M. K., Mandelin, J., Bono, P. & Hollmen, M., 1 Aug 2021, In: Clinical Cancer Research. 27, 15, p. 4205-4220 16 p.Research output: Contribution to journal › Article › Scientific › peer-review
Open AccessFile -
Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors An Analysis of a Randomized Clinical Trial After 10-Year Follow-up
Joensuu, H., Eriksson, M., Hall, K. S., Reichardt, A., Hermes, B., Schuette, J., Cameron, S., Hohenberger, P., Jost, P. J., Al-Batran, S-E., Lindner, L. H., Bauer, S., Wardelmann, E., Nilsson, B., Kallio, R., Jaakkola, P., Junnila, J., Alvegard, T. & Reichardt, P., Aug 2020, In: JAMA Oncology. 6, 8, p. 1241-1246 6 p.Research output: Contribution to journal › Article › Scientific › peer-review
-
Hypoxia-inducible factor (HIF)-prolyl hydroxylase 3 (PHD3) maintains high HIF2A mRNA levels in clear cell renal cell carcinoma
Miikkulainen, P., Högel, H., Seyednasrollah, F., Rantanen, K., Elo, L. L. & Jaakkola, P. M., 8 Mar 2019, In: Journal of Biological Chemistry. 294, 10, p. 3760-3771 12 p.Research output: Contribution to journal › Article › Scientific › peer-review
Open AccessFile